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Abstract 
Objective. The aim of this study was to explore the most distressing symptoms of systemic 
lupus erythematosus (SLE) and determine how these relate to health-related quality of life 
(HRQoL), anxiety/depression, patient demographics and disease characteristics (duration, 
activity, organ damage). 
Methods. In a cross-sectional study, patients with SLE (n=324, age 18-84 years) gave written 
responses regarding which SLE-related symptoms they experienced as most difficult. Their 
responses were categorized. Within each category, patients reporting a specific symptom were 
compared with non-reporters and analyzed for patient demographics, disease duration, results 
from the questionnaires: Medical Outcomes Study Short-Form 36, Hospital Anxiety and 
Depression Scale, Systemic Lupus Activity Measure, SLE disease activity index and the 
Systemic Lupus International Collaboration Clinics/American College of Rheumatology 
damage index. 
Results. 23 symptom categories were identified. Fatigue (51%), Pain (50%) and 
Musculoskeletal distress (46%) were  most frequently reported. Compared with non-reporters, 
only patients reporting Fatigue showed statistically significant impact on both mental and 
physical components of HRQoL.. Patients with no present symptoms (10%) had higher 
HRQoL (p<0.001) and lower levels of depression (p<0.001), anxiety (p<0.01) and disease 
activity (SLAM) (p<0.001). 
Conclusion. Fatigue, pain or musculoskeletal distress dominated the reported symptoms in 
approximately half of the patients. Only patients reporting Fatigue scored lower on both 
mental and physical aspects of HRQoL. Our results emphasize the need for further support 
and interventions to ease the symptom load and improve HRQoL in patients with SLE. Our 
findings further indicate that this need is particularly urgent for patients with symptoms of 
pain or fatigue. 
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INTRODUCTION 
Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease with individual 
variation of organ involvement (e.g., skin, joints, kidneys, nervous system and serous 
membranes) (1). Disease activity often varies over time and subjective symptoms are 
described as being prominent (2, 3). Both clinical care and research assessments are 
traditionally focused on predefined aspects of SLE (e.g., selected symptoms or aspects of 
disease impact) in which patients are asked to rate or assess different parameters according to 
chosen standards. When SLE disease activity and manifestation are assessed, the focus is 
often on objective signs and symptoms traditionally observed by physicians. There are 
however indications that several concepts of importance to patients (e.g. subjective 
symptoms) are not adequately captured by recommended measures of disease activity and 
health status (4, 5). This insight has contributed to today’s recommendation to incorporate 
patient-reported outcomes in research (6) in an effort to cover disease activity and impact 
more fully. In recent years a number of studies have sought to gain a better understanding of 
the aspects of living with SLE by involving the patient’s perspective and thus identify 
variations in the experience of SLE and disease-related symptoms. One example of this 
approach is the development of a SLE Specific Symptom Checklist (7-9), as well as other 
procedures used to identify disease-driven health issues identified by patients (10).  
 
To understand the consequences of patient-reported symptoms on disease impact data from 
health-related quality of life (HRQoL) questionnaires can be used. HRQoL includes several 
dimensions, physical as well as psychological, and represents a broad perspective of the 
overall impact of disease. HRQoL is an important complement to measures of disease activity 
and damage (11-13). For instance, comparative studies have shown that patients with SLE 
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perceive reduced HRQoL compared with controls and in parity with several other diseases 
(14-19).  
How the broad spectrum of SLE symptoms affects patients’ experience of HRQoL is not yet 
well understood. Different methods, as focus-groups and Delphi studies, have been used to 
capture aspects of SLE that are important to the patients (4, 20). Stamm et al (4) explored if 
important concepts of daily functioning per se are represented in the HRQoL and Bauernfeind 
et al (20) how important concepts could be identified by International Classification of 
Function (ICF). These studies did not explore if these concepts represent differences in self-
reported HRQoL. 
 
To contribute to the understanding of patients’ experience of SLE we aimed to explore the 
spontaneously most distressing symptoms of systemic lupus erythematosus (SLE) and to 
determine how these symptoms relate to HRQoL, anxiety/depression, patient characteristics 
(age, partner status) and disease characteristics (duration, activity and organ damage). 
 
 
PATIENTS AND METHODS 
The present study is part of an ongoing cohort project started in 2004 at Karolinska University 
Hospital Solna, where all patients with SLE have consecutively received an information letter 
and given the opportunity to participate. The patients gave their written consent in a reply-
paid envelope. Patients included in the cohort study from January 2004 to March 2010 were 
consecutively and continuously included in the present study. All patients were 18 years of 
age or older, Swedish speaking and writing, and fulfilled the American College of 
Rheumatology (ACR) 1982 revised criteria for SLE (≥4 ACR criteria) (21). Exclusion criteria 
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were difficulties to read and write Swedish. The study was approved by the regional ethical 
review board. 
At the study inclusion, the participants gave written answers to two open questions (“What 
SLE-related symptoms have you experienced as most difficult during your disease?” and 
“What symptoms do you presently perceive as most difficult?”). The patients also completed 
self-assessment measures of HRQoL, anxiety and depression (see below). These self-
assessments were followed by a physical examination, assessment of disease manifestations, 
activity and organ damage, all of which were performed by a rheumatologist. 
 
Self-assessment measures. The study used the self-assessment questionnaire Medical 
Outcomes Study Short-Form 36 (SF-36) to measure HRQoL (22). The SF-36 includes 36 
items divided into eight dimensions: physical functioning (PF), role physical (RP), bodily 
pain (BP), general health (GH), vitality (VT), social functioning (SF), role emotional (RE) 
and mental health (MH). Each dimension is rated on a scale from 0 to 100, were high values 
represent better HRQoL. The eight domains can also be divided into two summary scales, the 
Mental Component Summary scale (MCS) and the Physical Component Summary scale 
(PCS). The MCS represents by VT, SF, RE and MH and the PCS by PF, RP, BP and GH. The 
SF-36 standard version representing health status for the past four weeks was used. 
The Hospital Anxiety and Depression Scale (HADS) (23, 24) consists of 14 items, equally 
divided into two scales (an anxiety scale and a depression scale). The range for each scale is 
0-21: the cut-off for normal values is described to be 7. According to standard protocol, the 
respondents were requested to answer each item based on their feelings during the past week. 
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Disease-specific measures. At the inclusion visit, the physicians performed all the disease-
specific assessments. Two instruments were used to assess disease activity: the Systemic 
Lupus Activity Measure (SLAM) (25, 26) and the SLE disease activity index (SLEDAI) (27). 
The SLAM covers clinical symptoms during the past month, including laboratory parameters, 
organ manifestations and some subjective symptoms such as fatigue and headache. It is 
divided into nine areas (score range 0-86, with high values representing a higher level of 
activity). SLEDAI includes 24 items corresponding to nine organ systems (score range 0-
105). We chose to use both of these two frequently used instruments due to indications that 
SLAM is more sensitive to changes important to patients (28) but SLEDAI is more frequently 
used. 
To assess cumulative organ damage the Systemic Lupus International Collaboration 
Clinics/American College of Rheumatology (SLICC/ACR) damage index was used. This 
index includes 12 organ systems with scores ranging from 0 to 47 (29, 30).  
 
Data analysis. The study used a mixed method approach representing of data from free 
written answers as well as standardized questionnaires. The data collection of the written 
answers were inspired from the free-listing methods originally used in anthropology and also 
used and described in oncology in the collection of patient reported symptoms from persons 
with e.g. lung cancer (31). The method of using an open question was applied to capture 
spontaneous answers from the respondent.  
 
The approach to process the written answers from the open questions emanated from an 
inductive procedure of mixed method (31) and conducted as follows. To increase the study’s 
validity independent researchers (LEE, ML, CM) with experience in qualitative methods in 
other fields than rheumatology were involved in the process to uncover patients’ symptom 
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descriptions. Using an inductive approach, the answers from the initial 200 respondents (i.e. 
the number of included patients at the time) were classified by the principal author (SP) 
according to content similarities. The inductive process and the result of “groups of patient 
answers” were discussed between SP and the last author (EWH), resulting in a preliminary 
coding list. The preliminary coding list was tested and used by another author (LEE) as a pilot 
to categorize answers from the 300 first responders, followed by suggestions used to adjust 
and clarify distinctions between the codes. The adjusted coding list was discussed and revised 
by several of the authors (SP, ML and EWH). Finally, SP, ML and CM each coded 25% of 
the statements from the 320 consecutive respondents included in the project. Cohen’s kappa 
was calculated and the majority of the coding categories had good to very good agreement 
(from 0.74 to 1.0). In four symptom categories agreement was moderate, these were all 
reported by only few patients (n≤6) (32). Using the final coding list, SP coded all statements 
the 320 respondents and four later included patients giving the final number of 324 
respondents.  
 
The second of the two open questions referred to present time (“What symptoms do you 
presently perceive as most difficult?”). Because several parameters could possibly change 
over time, statements from this question were used when comparing the symptom categories 
with the patients’ answers from the questionnaires. Two categories were excluded from the 
comparative analysis: Allergy (not reported by any respondents as present at time of inclusion 
in the study) and Discomfort (reported by one respondent as a current problem at inclusion). 
The Wilcoxon Signed Ranks test was applied to compare individual responses within each 
symptom category between the first and second open question (symptom ever vs. present 
symptom).  
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To explore the symptom categories comparisons were conducted between reporters (patients 
with a written statement in a specific symptom category) and non-reporters (patients 
reporting any other symptom but not the specific symptom investigated) within the symptom 
categories using the Mann-Whitney U test.  
 
The collected quantitative data were mostly categorical, nominal or ordinal and therefore non-
parametric tests were used. Medians with interquartile ranges (IQRs) are presented for 
numerical data and percent is used for frequency data. The quantitative data from the 
questionnaires were analyzed using the Statistical Package for the Social Sciences (SPSS, 
Chicago IL, USA), version 15.  
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RESULTS 
Participants.  
This study included  a total of 324 patients with SLE: median age 48 years (IQR 35-58), 
median disease duration 12 years (IQR 5-22) and median number of fulfilled SLE criteria 6 
(IQR 5-7). Demographic variables are presented in Table 1 and the results from the self-
assessments of health related quality of life (HRQoL), anxiety and depression are summarized 
in Table 2. 
 
Patients’ report of symptom distress.  
Twenty-three symptom categories were identified from the respondents’ answers to the open 
questions (Table 3). The three most frequently reported symptom categories were Fatigue, 
Pain and Musculoskeletal distress (Table 3). The median number of reported categories 
corresponding to the question of ever-present symptoms was 3 (IQR 2-4). The patients 
reported fewer (p<0.001) symptom categories as being present at the time of study inclusion 
(median 2, IQR 1-3) compared with symptom categories reported as ever-present. A majority 
of the patients (n=255, 78.7%) described at least one of the top three most frequently reported 
symptom categories (Fatigue, Pain and Musculoskeletal distress) as being an ever-present 
problem.  
 
We investigated whether patients reported the same symptoms as present at the time of study 
inclusion and compared this with symptoms ever experienced (Table 3). In half of the 
symptom categories the respondents did not change their answer. In six categories (Fatigue, 
Pain, Psychological/emotional, Cognitive, Reproduction and Sleeping disorder) over 45% of 
the respondents described the complaint as both an ever-present distress and as one of the 
presently most distressing symptoms.  
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One tenth of the patients stated that they perceived no present symptom at time of inclusion in 
the study.  
 
Symptom distress compared with demographic data  
Present symptoms were further evaluated by comparing patients who reported a specific 
symptom with patients who did not report a specific symptom. The reporters in each symptom 
category were also compared in relation to age, disease duration and partner status. Patients 
reporting Cognitive distress at inclusion in the study had shorter disease duration (median 4 
years, IQR 1-17, p=0.04) than patients reporting other symptoms (median 12 years, IQR 5-
21). Only three patients reported present problems with Reproductive distress, all with a 
disease duration of less than 1 year. The question of present symptoms was not answered (i.e. 
left blank) by 16.3 % of the patients and was therefore separately analyzed. Patients who did 
not answer the question regarding present SLE-related symptoms (n=53) at inclusion had a 
longer disease duration (median 18 years, IQR 7.5-25.5) than patients reporting any SLE-
related symptom (median 11 years, IQR 4.5-21; p= 0.009). There were no statistically 
significant differences in age or partner status within any of the symptom categories (data not 
shown).  
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Symptom distress compared with disease characteristics 
The symptom categories were further analyzed for disease activity, disease duration and organ 
damage (Table 4). When comparing reporting patients with non-reporting patients within each 
symptom category (see data analysis), reporting patients in the categories Fatigue, Pain 
Musculoskeletal, Swelling, Psychological/emotional, Fever, Cognitive Distress and Sleeping 
had higher disease activity as measured by SLAM. Only patients reporting Reduced physical 
capacity had more extensive organ damage (SLICC/ACR, median=3, IQR 0.5-5, p=0.008) 
than those not reporting the corresponding symptom category (no reduced physical capacity: 
SLICC/ACR, median=1, IQR 0-2). Patients who reported no present symptoms of SLE had 
lower disease activity (SLAM, median=3, IQR 2-6, p<0.001) and organ damage 
(SLICC/ACR, median=0, IQR 0-1, p<0.05) than patients reporting any kind of symptom 
(SLAM, median=7, IQR 4-10; SLICC/ACR, median=1, IQR 0-2), but no differences in 
disease duration. 
 
Symptom distress compared with measurements of anxiety, depression and HRQoL 
Each category was subsequently compared with results from the anxiety, depression (Table 4) 
and HRQoL self-assessment questionnaires (Table 5 and supplementary data). Patients with 
present Psychological/emotional distress had the highest anxiety levels (n= 22) (HADS 
anxiety median=9.5, IQR 5.75-14) compared with those without psychological/emotional 
distress (HADS anxiety median=6, IQR 3-9) (p=0.005). In comparison with the patients 
reporting any symptom, the no-symptom patients showed higher HRQoL, less anxiety and 
less depression (Tables 4 and 5). The groups did not differ in age. 
 
The three most frequently reported symptom categories (Fatigue, Pain and Musculoskeletal 
distress) were associated with reduced HRQoL (Table 5). Patients with Fatigue reported 
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significantly lower scores (meaning worse) in both MCS and PCS and higher scores (meaning 
worse) on the questionnaires measuring anxiety and depression. Patients reporting Pain had 
lower scores on PCS and more depression but not more anxiety. Patients in the symptom 
category Musculoskeletal distress reported reduced PCS. Because Fatigue and Pain were 
symptoms that might interact, they were further analyzed as subgroups, leaving out those 
patients who reported both fatigue and pain. The statistically significant differences between 
the subgroups were detected into the dimensions of Bodily Pain and Vitality (Supplementary 
data). Respondents reporting Fatigue (n=65) but not Pain scored lower on Vitality (p=0.013), 
whereas respondents reporting Pain (n=45) but not Fatigue scored lower on Bodily Pain 
(p=0.003). Notable here is that lower levels on these domains indicate more or worse impact, 
meaning that the results from the questionnaires were congruent with the symptoms 
spontaneously reported by the patients. 
 
DISCUSSION 
In the responses to the open-ended questions over 75% (n=255) of the SLE patients reported 
Fatigue, Pain or Musculoskeletal distress as the most difficult symptoms. Only patients 
reporting fatigue scored lower on both mental and physical aspects of HRQoL. Other 
symptom categories showed statistically significant impact on either the mental or the 
physical components of HRQoL. Noteworthy, 10% of the patients reported that they 
perceived no SLE symptom at the time of study inclusion. This latter finding is consistent 
with the finding that these patients also had lower disease activity and higher HRQoL. In 
recent years there has been several improvements in the treatment of patients with SLE (33, 
34), but the new therapies do not appear to have changed the fact that fatigue and pain are still 
perceived as the most distressing symptoms. Our results emphasize the need for further 
support and interventions to recognize and ease symptom load and thus improve the HRQoL 
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of patients with SLE. Further, the results indicate that the need is particularly urgent for 
patients with symptoms of pain or fatigue.  
 
To our knowledge, this is the so far largest cohort study focusing on patients’ self-report of 
SLE-related symptoms which provided us with data representing a heterogenic variation of 
patient-reported distress. The results are based on data from only one cohort, which calls for 
caution concerning the generalizability. However, the results from our study are strengthened 
by similarities to the symptoms identified in other studies (7, 20). In the study of 
Grootscholten et al 89% of the patients reported fatigue, 61% painful joints and 54% painful 
muscles (7). Their symptom category “loss of concentration” (reported by 54%) has 
similarities to our category Cognitive distress (reported by 5%). Their result presented the 
highest scores for perceived burden of single symptoms as related to fatigue but also 
sensitivity to sunlight and disturbed memory. At least six of our categories were not clearly 
described in the lupus specific symptom checklist (7) (Kidney function, Reduced physical 
capacity, Fever, Infections, Treatment/examination, Forced adaptation or dependence). 
Stamm et al (4) used the World Health Organization’s International Classification of 
Functioning, Disability and Health (ICF) as a framework to sort “concepts of importance” 
collected from persons with SLE. The authors pointed out that environmental factors are not 
covered by standard measures suggested for SLE (35) and specifically mentioned medication 
to be an environmental factor. Our symptom category distress related to 
Treatment/examination could be considered as such an environmental factor reported by 
patients as having distressing impact. In future studies it would be informative to compare 
patients’ reports of symptoms with nursing diagnostic terms (e.g., the North American 
Nursing Diagnosis Association, NANDA) (www.nanda.org). 
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Patients reporting Fatigue and Pain in the present study scored lower than non-reporting 
patients on self-assessments of HRQoL. This finding is consistent with previous studies 
showing that pain and fatigue influenced HRQoL in patients with SLE (3, 36). Fatigue and 
pain are thus well-known symptoms that need more attention if we strive to improve the care 
of patients with SLE. It is possible that we would have obtained similar results using SLE 
specific instruments such as SLEQOL or LupusQoLto assess HRQoL (37, 38) but at the time 
for data collection they were not available in Swedish. Also, an approach using pre-defined 
answers would not have allowed us to explore spontaneous answers from the informants.  
 
In clinical care as well as in research, attention must be paid to how questions are posed to 
patients. It was previously demonstrated that physicians only detect 62% of the most 
important health outcomes in SLE as reported by individual patients (39). Our approach with 
open questions without fixed answer alternatives reflects the patient’s experiences of 
symptoms. This approach makes it possible to enlighten and detect problem areas neglected 
by physicians, but crucial to the individual patient. A potential limitation of our study is that 
the results are dependent on how the respondents interpret the questions. Interpretations are 
based on the patients’ knowledge, individual perception and personal thoughts of their 
disease-related distress. A previous study has shown a discrepancy between patients and 
physicians’ selection of important health and symptom outcomes (39). This discrepancy has 
also been illustrated in the fact that even when physicians incorporate aspects of what patients 
tell them, a discrepancy was found between patients and physicians assessment of disease 
activity (40). When evaluating disease activity, patients are influenced by their psychological 
and physical well-being. Physicians, on the other hand, score disease activity based on the 
clinical and physical signs and symptoms of lupus (41, 42). It is however important to recall 
that some patient reported symptoms are manifestation of active disease, and is therefore not 
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surprisingly significantly associated with disease activity measures. To further explore 
patients’ experience of symptom distress, it would be interesting to give physicians the same 
possibility to answer an open question of the patients’ most distressing symptom and compare 
this with the perceptions of the patients. In future studies it would also be valuable to follow 
symptom reports over time, using the procedure with an open question to allow detection of 
symptom change and distress over time, as well as to increase the possibility to uncover 
symptoms reported by only a few patients. 
 
To conclude, patients with SLE reported a multitude of distressing symptoms, many of which 
are not covered by present measures of disease activity. The three most frequently reported 
symptom categories (i.e. Fatigue, Pain and Musculoskeletal distress) were associated with 
lower HRQoL, however only patients reporting Fatigue showed impact on both mental and 
physical components of HRQoL. Notably, one tenth of the patients reported that they did not 
perceive having present symptoms of SLE, and this group also had less disease activity and 
better HRQoL. We suggest that open questions should be used as a complement to standard 
measures of disease activity in order to facilitate communication and capture the patient’s 
perspective of disease-related distress.
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Table 1 Characteristics of patients with SLE (n=324) 
 % median (IQR) range 
Age (yrs)   48 (35-58) 18-84 
Women 91%    
Living with partner  57 %    
Disease duration (yrs)   12 (5-22) 0-58 
SLE criteria  6 (5-7) 4-10 
SLAMa  6 (4-10) 0-27 
SLEDAIb   2 (0-6) 0-26 
SLICCc   1 (0-2) 0-10 
Lupus manifestation     
Malar rash  54%    
Discoid rash  19%    
Photosensitivity  67%    
Oral ulcers  34%    
Arthritis  83%    
Pleuritis  36%    
Pericarditis  18%    
Nephritis  40%    
Neurology d 11%   
Blood manifestation e 69%   
Ongoing medicationf    
Chloroquine  32%    
Cyclophosfamide p.o.  2%    
 25 
Cyclophosfamide i.v.  11%   
Azathioprine  19%    
Methotrexate  4%    
Mycofenolatmofetil  7%    
Ciclosporin  2%    
Rituximab (ever) 8%    
Steroid dose mg, median (IQR)   3.4 (0-7.5)  
aSystemic Lupus Activity Measure (25, 26), bSLE disease activity index (27), csystemic 
lupus International collaboration Clinics/American College of Rheumatology 
(SLICC/ACR) damage index (29, 30), dpsychosis or seizures, eleukopenia, 
thrombocytopenia, lymphopenia or hemolytic anemia, fongoing treatment with disease-
modifying antirheumatic drugs (DMARDs) 
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Table 2 Patients’ self-assessment of health related quality of life a,, anxietyb and depressionb 
(n=324) 
   Median IQR 
     
Physical Functioning(PF)a   75 50-90 
Role Physical (RP)a   50 0-100 
Bodily Pain (BP)a   52 41-84 
General Health (GH)a   42 25-62 
Vitality (VT)a   40 25-60 
Social Functioning SF)a   75 50-100 
Role Emotional (RE)a   100 0-100 
Mental Health (MH)a   72 52-84 
Mental Component Summary (MCS)a,c  44 (33-53) 
Physical Component Summary (PCS)a,d  39 (29-50) 
HADSb depression   4 2-7 
HADSb anxiety   6 3-9 
aDimension and summary component from Medical Outcomes Study Short-Form 36 (SF-36), 
scale 0-100 (22). bHospital Anxiety and Depression scale, scale 0-21, cut-off ≥7 (23, 24). 
cMCS represents by VT, SF, RE, MH. dPCS represents by PF, RP, BP, GH. 
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Table 3 Categories of patient-reported symptomsa related to SLE (n=324). Symptoms 
reported as most difficult ever and compared with most difficult at the present time 
Category name Ever  Present  P-valueb  
 n (%)c n (%)c  %d 
Missing/no answer 16 (4.9) 53 (16.4)   
Fatigue 165 (50.9) 124 (38.3) 0.058 64 
Pain 162 (50.0) 104 (32.1) <0.001 49 
Musculoskeletal 148 (45.7) 102 (31.5) 0.017 40 
Skin, hair or nails 77 (23.8) 39 (12.0) 0.001 33 
Lungs 47 (14.5) 26 (8.0) 0.016 28 
Eyes or mouth 38 (11.7) 23 (7.1) 0.074 40 
Heart or circulation 34 (10.5) 18 (5.6) 0.194 15 
Neurological distress 33 (10.2) 21 (6.5) 0.289 43 
Kidney function 32 (9.9) 6 (1.9) <0.001 16 
Swelling  28 (8.6) 10 (3.1) 0.001 25 
Reduced physical capacity 28 (8.6) 16 (4.9) 0.008 29 
Blood (cells/vessels) 24 (7.4) 5 (1.5) <0.001 17 
Psychological/emotional distress 24 (7.4) 22 (6.8) 0.808 46 
Fever 19 (5.9) 9 (2.8) 0.012 26 
Infections 16 (4.9) 4 (1.2) 0.002 19 
Cognitive distress 15 (4.6) 17 (5.2) 0.705 80 
Treatment/examination 11 (3.4) 7 (2.2) 0.317 0 
Gastro-intestinal distress  11 (3.4) 6 (1.9) 0.527 9 
Forced adaptation or dependence 9 (2.8) 8 (2.5) 0.317 11 
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Discomfort 8 (2.5) 1 (0.3) 1.000 13 
Reproduction 5 (1.5) 3 (0.9) 0.157 60 
Allergy 2 (0.6) 0 - - 0 
Sleeping disorder 2 (0.6) 5 (1.8) 1.000 50 
aAnalysis of answers from the two questions: ever: “What SLE-related symptoms have you 
experienced as most difficult during your disease? Present: “What symptoms do you 
presently perceive as most difficult?” bWilcoxon Signed Ranks Test for change in answer,  
cpercent of all patients, dpercent of patients reporting symptom distress as ever distressing 
as well as present distress.  
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Table 4 Present symptoms reported by patients with SLE (n=324) and compared with 
patients’ self-assessment of depression a, anxiety b physicians’ assessment of SLE activityc,d 
and organ damagee. 
Category name Depressiona Anxietyb SLAMc SLEDAId SLICC/ACRe 
No present symptom f 1.5*** 4** 3*** 2 0* 
Fatigue 5*** 6.5* 7** 2 1 
Pain 5** 6 7*** 4** 1 
Musculoskeletal 4 6 7** 3 1 
Neurological 5* 7 6 2 1 
Swelling  4.5 8 8.5* 7* 1 
Reduced capacity 3.5 1* 7 3 3** 
Blood (cells or vessels) 1* 4 10.5 3.5 0 
Psychological/emotional 6.5** 9.5** 9** 2 1 
Fever 5 5 14*** 6* 1 
Cognitive  7** 6 10** 4 2 
Sleeping 13.0* 10** 15** 9* 0 
Median value from patient reporting a symptom compared with non-reporters of that 
symptom category. Only categories with statistically significant difference are shown. Bold = 
significant difference between non-reporters and reporters with-in the category. Significance 
level: *** p<0.001, ** p<0.01, * p<0.05, Mann-Whitney U test. aDepression from Hospital 
Anxiety and Depression scale (23, 24), banxiety  from Hospital Anxiety and Depression scale 
(23, 24), cSystemic Lupus Activity Measure (25, 26), dSLE disease activity index, (27), e the 
Systemic Lupus International Collaboration Clinics/American College of Rheumatology 
(SLICC/ACR) damage index (29, 30). fNo present symptom = patients given a clear 
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description of no SLE-related symptom at inclusion compared with patients reporting any 
symptom.  
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Table 5 Distress reported from patients with SLE at inclusion of study grouped by symptom 
category and compared with self-assessment of quality of lifea (n=324) 
 MCS 
Median 
(IQR) 
p-valueb PCS 
Median 
(IQR) 
p-valueb 
No symptom c 52 (46-56) <0.001 54 (51-57) <0.001 
Fatigue 40 (25-48) <0.001 37 (29-46) 0.002 
Pain  43 (27-52) 0.187 34 (25-41) <0.001 
Musculoskeletal 43 (30-54) 0.850 34 (26-42) <0.001 
Skin/hair/nails  45 (32-51) 0.504 43 (31-52) 0.384 
Lungs 47 (30-56) 0.547 33 (24-48) 0.040 
Eyes/mouth  45 (31-55) 0.583 44 (32-52) 0.334 
Heart or circulation 36 (26-47) 0.106 33 (27-43) 0.065 
Neurological 33 (24-49) 0.049 36 (29-41) 0.139 
Kidney  54d (50-60) 0.036 36 (19-49) 0.561 
Swelling 27 (23-51) 0.214 35 (26-41) 0.098 
Reduced physical capacity 49 (28-60) 0.219 25 (15-36) <0.001 
Blood  52 (45-57) 0.103 46 (26-52) 0.821 
Psychological/emotional 37 (24-43) 0.005 33 (30-49) 0.427 
Fever 40 (34-48) 0.404 26 (18-32) 0.001 
Infections 39 (14-51) 0.429 35 (20-43) 0.281 
Cognitive  39 (25-44) 0.033 34 (30-42) 0.156 
Treatment/examination 44 (30-55) 0.872 23 (15-27) 0.009 
Gastro-intestinal 41 (27-52) 0.716 38 (22-50) 0.695 
Forced adaptation or dependence 31 (25-58) 0.733 36 (15-46) 
 32 
Sleep 33 (18-38) 0.074 25 (14-44) 0.094 
aSubscales of SF-36: MCS=Mental Component Scale, PCS=Physical Component Scale (22), 
bMann-Whitney U test. cNo symptom= patients given a clear description of no SLE-related 
symptom at inclusion of the study compared with patients reporting any symptom. Symptom 
groups excluded from this table: Discomfort (only one person), Allergy (reported by none), 
Reproduction (only three respondents). d better HRQoL than non-reporters (other categories 
with statistically significant difference represent worse HRQoL than non-reporters). Bold= 
significant difference between non-reporters and reporters with-in the category. Numbers of 
patients reporting in each symptom category see Table 3 and the column Present. 
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Supplementary Material: Distress reported from patients with SLE at inclusion of study 
grouped by symptom category and compared with self-assessment of quality of lifea (n=324) 
Category  PF RP BP GH VT SF RE MH 
No symptomb. 95*** 100*** 100*** 77*** 70*** 100*** 100*** 84*** 
No answerc 65 50 51 40 40 62.5 100 72 
Fatigue 70** 25*** 47** 37*** 30*** 50*** 50*** 64*** 
Pain 65*** 25*** 41*** 34*** 35*** 63*** 67 64* 
Musculoskeletal 65*** 25*** 41*** 35** 40 63* 66.7 68 
Skin/hair/nails 80 50 52 45 45 4575 100 72 
Lungs 58 25 41 33* 40 56 67 72 
Eyes or mouth 85 87.5 62 45 50 75 100 72 
Heart/circulation 70 0* 41* 30* 30 38** 33 60 
Neurological 70 12.5* 41* 37 40 50** 0* 60 
Kidney 80 33 74 17 45 88 100 84 
Swelling 70 25 41* 30 40 4* 0 56 
Reduced capacity 35*** 0* 31** 30* 20 50 100 52 
Blood 85 50 84 67 60 100 100 *92 
Psychol./emotional 65 13 51 37 33 38** 33* 50** 
Fever 60* 0** 31** 27* 15** 25** 67 60 
Infection 63 13 48 28 35 25* 50 76 
Cognitive 65 13 41 40 25** 50 33* 60* 
Treatment/examin. 25** 0 31 25 40 62.5 100 64 
Gastro-intestinal 60* 0 36.5 42 33 38 0 78 
Forced adaptation  60 25 22* 42 23* 63 67 42 
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Sleep 35 12.5 0 15 10 13 0* 40* 
a dimensions of SF-36: PF=Physical functioning, RP=Role Physical, BP=Bodily Pain, 
GH=General Health, VT=Vitality, SF=Social Functioning, RE=Role Emotional, MH=Mental 
Health (22), bNo symptom= patients given a clear description of no SLE-related symptom at 
inclusion of the study compared with patients reporting any symptom, cNo answer= patients 
did not answer the question of SLE-related symptom distress compared with patients 
reporting any symptom distress. Reduced capacity= Reduced physical capacity, Blood = 
blood cells or vessels. Psychol./emotional= Psychological or emotional distress, Cognit = 
Cognitive distress, Treatment/examin.= Distress related to Treatment or examination, GI= 
Gastro-intestinal distress, Forced adaptation = Forced adaptation or dependence, Sleep= 
Sleeping disorder. Bold= significant difference between non-reporters and reporters with-in 
the category. Significance level: *** p<0.001, ** p<0.01, * p<0.05, Mann-Whitney U test. 
Symptom groups excluded from this table: Discomfort (only one person), Allergy (reported 
by none), Reproduction (only three respondents). 
 
 
